Literature DB >> 9535299

Relaxation therapy in Tourette syndrome: a pilot study.

A Bergin1, H R Waranch, J Brown, K Carson, H S Singer.   

Abstract

To evaluate the feasibility and efficacy of behavioral relaxation therapy as treatment for Tourette syndrome, 23 patients were recruited from a university-based pediatric Tourette syndrome referral clinic. Individuals were randomized and stratified according to initial tic severity and the presence of attention-deficit hyperactivity disorder into either relaxation therapy or a minimal therapy (control) group. Sixteen patients, mean age 11.8 years (S.D. 2.8 years), completed the 3-month study, which included weekly, hour-long, individual training sessions for 6 weeks. Individuals (n = 7) in the relaxation therapy group demonstrated a significantly increased ability to relax, compared with the minimal therapy (awareness and quiet time training) group. At 6 weeks, tic findings, based on five established tic severity scales, revealed greater improvement in the relaxation treatment group, but values failed to reach statistical significance. No difference between therapy groups was apparent at the 3-month evaluation. The acquired ability to relax did not significantly affect behavioral measures on the Child Behavioral Checklist. On the basis of this pilot study, relaxation therapy appears to have a limited role in the treatment of tics in Tourette syndrome.

Entities:  

Mesh:

Year:  1998        PMID: 9535299     DOI: 10.1016/s0887-8994(97)00200-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  15 in total

1.  European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions.

Authors:  Cara Verdellen; Jolande van de Griendt; Andreas Hartmann; Tara Murphy
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-04       Impact factor: 4.785

Review 2.  Tourette syndrome: clinical characteristics and current management strategies.

Authors:  E H Kossoff; H S Singer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

3.  Bridging neuroscience and clinical psychology: cognitive behavioral and psychophysiological models in the evaluation and treatment of Gilles de la Tourette syndrome.

Authors:  Marc E Lavoie; Julie Leclerc; Kieron P O'Connor
Journal:  Neuropsychiatry (London)       Date:  2013-02-01

Review 4.  Update on attention-deficit/hyperactivity disorder and tic disorders: a review of the current literature.

Authors:  Heather A Simpson; Leah Jung; Tanya K Murphy
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

Review 5.  Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Authors:  M M Robertson; J S Stern
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

6.  Treatment of tics and tourette syndrome.

Authors:  Harvey S Singer
Journal:  Curr Treat Options Neurol       Date:  2010-11       Impact factor: 3.598

Review 7.  Pharmacological options for the treatment of Tourette's disorder.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.

Authors:  Tamara Pringsheim; Yolanda Holler-Managan; Michael S Okun; Joseph Jankovic; John Piacentini; Andrea E Cavanna; Davide Martino; Kirsten Müller-Vahl; Douglas W Woods; Michael Robinson; Elizabeth Jarvie; Veit Roessner; Maryam Oskoui
Journal:  Neurology       Date:  2019-05-07       Impact factor: 9.910

Review 9.  Behavior therapy in tic-disorders with co-existing ADHD.

Authors:  Manfred Döpfner; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-06       Impact factor: 4.785

10.  Cognitive-behaviour therapy and skilled motor performance in adults with chronic tic disorder.

Authors:  Kieron P O'Connor; Marc E Lavoie; Emmanuel Stip; François Borgeat; Anick Laverdure
Journal:  Neuropsychol Rehabil       Date:  2008-01       Impact factor: 2.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.